The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A tripeptide consisting of an Ile-Ile-Thr-NH2 sequence N-substituted on the threonamide amidic nitrogen with a (2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl group and with acetyl and methyl groups on the nitrogen of the isoleucine residue distal to the threonamide; a naturally occurring selective proteasome inhibitor with anti-inflammatory activity.
epoxomicin inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein] epoxomicin affects the localization of AHR protein
epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of ATF4 protein]]
epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of BAX protein]]
epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of BCL2 protein]]
epoxomicin results in increased expression of BIRC5 protein epoxomicin inhibits the reaction [Aspirin results in decreased expression of BIRC5 protein]
epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased cleavage of and results in increased activity of CASP3 protein]]
epoxomicin results in increased expression of CDH1 protein NFE2L2 protein alternative form inhibits the reaction [epoxomicin results in increased expression of CDH1 protein]
epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of EIF2AK3 protein]]
epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of EIF2S1 protein]]
epoxomicin inhibits the reaction [troxerutin inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased phosphorylation of ERN1 protein]]
epoxomicin inhibits the reaction [scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; epoxomicin inhibits the reaction [scutellarin results in decreased expression of HIF1A protein] epoxomicin results in increased expression of HIF1A protein
epoxomicin results in increased expression of and affects the localization of NFE2L1 protein; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMA2 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMC4 mRNA] NFE2L1 alternative form affects the reaction [epoxomicin results in increased expression of NFE2L1 protein alternative form]
epoxomicin results in increased expression of NFE2L2 protein NFE2L2 protein alternative form inhibits the reaction [epoxomicin results in increased expression of CDH1 protein]
epoxomicin inhibits the reaction [Potassium results in increased secretion of PDYN protein alternative form]; epoxomicin results in decreased expression of and results in decreased secretion of PDYN protein alternative form epoxomicin results in decreased expression of PDYN protein alternative form
epoxomicin inhibits the reaction [resveratrol results in decreased expression of PPARG protein]; epoxomicin inhibits the reaction [rosiglitazone results in decreased expression of PPARG protein]
epoxomicin results in decreased expression of PRKN mRNA epoxomicin inhibits the reaction [PRKN protein results in decreased susceptibility to Ceramides]
epoxomicin results in increased expression of PSMB6 mRNA Ascorbic Acid inhibits the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; NFE2L1 protein affects the reaction [epoxomicin results in increased expression of PSMB6 mRNA]; sulforaphane inhibits the reaction [epoxomicin results in increased expression of PSMB6 mRNA]
epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of SP1 protein]; epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in increased degradation of SP1 protein] epoxomicin results in increased ubiquitination of SP1 protein
epoxomicin inhibits the reaction [5-(4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)-3-methoxybenzylidene)thiazolidine-2,4-dione results in decreased expression of TAF1 protein]
epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein]
browse the term
